07:09 EDT Insmed (INSM) backs FY25 global ARIKAYCE revenue view $405M-$425M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- INSM Upcoming Earnings Report: What to Expect?
- Insmed says NEJM publishes ‘positive’ results from Phase 3 ASPEN study
- Insmed’s Brensocatib: A Promising Solution for Bronchiectasis in AATD Patients
- Insmed’s Strategic Positioning and Growth Potential Justify Buy Rating Despite Leadership Change
- Insmed’s Chief Commercial Officer Resigns for Personal Reasons